Maria Berkman

Dr. Berkman is Director and Head of the MedTech practice at Broadview Ventures, where she shares responsibility for all aspects of Broadview’s investment activity, from identification and screening of new opportunities, through due diligence, negotiation of deal structure, and portfolio company board involvement.

Prior to joining Broadview Ventures, Dr. Berkman was a management consultant at Monitor Group, where she specialized in life sciences with a focus on corporate, franchise, and asset-level commercialization strategy and competitive strategic planning for BioPharma and MedTech clients. Previously, Dr. Berkman trained within the Partners HealthCare System at Newton Wellesley Hospital in General Surgery.

In addition to her role at Broadview Ventures, Dr. Berkman contributes time as a SBIR/STTR grant reviewer for the National Science Foundation and is a Strategic Advisory Board Member for the RAD BioMed Accelerator in Tel Aviv, Israel. Dr. Berkman also serves on the boards of Adient, Aria CV, FineHeart, Vascular Graft Solutions and Vectorious, and previously served on the boards of Apama (acquired by Boston Scientific) and Capricor (NASD:CAPR).

Dr. Berkman earned an MD from the UCLA School of Medicine, graduating Alpha Omega Alpha with a research focus in cardiothoracic and trauma surgery, and earned an MBA from the Anderson School of Management at UCLA.